Isotechnika Pharma Inc IPHAF

NEWS

[stockman6]

14:15 EDT Monday, April 29, 2002 EDMONTON, April 24 /CNW/ - Mr. Joseph Koziak, Executive Vice President of Isotechnika Inc. reported today that the United States Federal Trade Commission has approved the agreement for the global co-development of Isotechnika's innovative transplant drug, ISA(TX)247, recently signed by Isotechnika and Roche. The granting of this regulatory approval enables the two companies to move forward with their plans to advance the clinical development and commercialization of ISA(TX)247. "This approval is great news for Isotechnika and Roche and for transplantation patients around the globe" states Mr. Koziak. "This judgment validates the continuing need in the market place and the world transplant community for a novel and innovative new medicine possessing greater potential therapeutic benefit to patients. Our future collaboration on the clinical advancement and commercialization of ISA(TX)247 capitalizes on the research and development strength of Isotechnika and the proven track record and commitment of Roche to the transplantation field."